OF
EWTX icon

Optimize Financial’s Edgewise Therapeutics EWTX Stock Holding History

Optimize Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,679
Closed -$687K – 364
2025
Q4 		$687K Buy
27,679
+396
+1% +$7.95K 0.35% 70
2025
Q3 		$443K Buy
+27,283
New +$387K 0.23% 163
2025
Q1 		– Sell
-12,062
Closed -$322K – 246
2024
Q4 		$322K Buy
+12,062
New +$384K 0.24% 127

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Optimize Financial's EWTX Position: Q1 2026 in Review

Optimize Financial sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 27,679 shares — an estimated $687K sold.

Optimize Financial first reported a position in EWTX in Q4 2024 and held it in 3 quarters. The position peaked at $687K in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Optimize Financial reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Optimize Financial sold 27,679 Edgewise Therapeutics shares in Q1 2026, an estimated $687K.
  • Optimize Financial first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 3 quarters.
  • Optimize Financial's Edgewise Therapeutics position peaked at $687K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.